ADVFN - Advanced Financial Network.
HOME» NYSE » J » JNJ Stock Price » JNJ Stock News

Johnson & Johnson Share News

 Johnson & Johnson Stock Price
JNJ Stock Price
 Johnson & Johnson Stock Chart
JNJ Stock Chart
 Johnson & Johnson Stock News
JNJ Stock News
 Johnson & Johnson Company Information
JNJ Company Information
 Johnson & Johnson Stock Trades
JNJ Stock Trades

J&J CEO: Will Make Any Changes Needed After Recall

DOW JONES NEWSWIRES Johnson & Johnson's (JNJ) chief executive vowed to make whatever changes are needed for its manufacturing processes to meet consumers' expectations and the company's own standards, saying it has hired independent quality experts to help. The company recalled about 1,500 lots of bottled products last week, including pediatric versions of Tylenol, Motrin, Zyrtec and Benadryl. Its McNeil Consumer Healthcare unit said it was withdrawing the over-the-counter products, starting late last Friday, because of manufacturing problems at its Fort Washington, Pa., plant In an open letter Friday to all those who use J&J products on the firm's corporate blog, Chairman and Chief Executive Bill Weldon called the recalls a disappointment to him and the rest of the company and its workers. "I have been assured that the chance of a serious medical event from the recalled products is remote," he said. "Even so, this does not give us comfort; one of our companies has let you down." He reiterated that McNeil suspended manufacturing at the Pennsylvania plant and has hired independent quality experts to help the facility return to the proper standards and also reevaluate the systems and manufacturing processes across the organization. He ended the note by saying the company "will work hard to earn back your confidence." A House committee said earlier this week it is opening an investigation into conflicting accounts of what had prompted the recall, as well as how the company handled consumer complaints about foreign matter in the bottles. Johnson & Johnson shares were up 0.2% at $63.42 in after-hours trading. The stock is down modestly so far this year. Johnson & Johnson blog: -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Johnson & Johnson (JNJ)
10/13/201512:48:00Johnson & Johnson's Profit Hit By Forex Headwinds -- 3rd Update
10/13/201509:39:00U.S. Hot Stocks: Hot Stocks to Watch
10/13/201509:20:00Forex, Competitive Headwinds Hit Johnson & Johnson's Profit...
10/13/201508:24:54Current Report Filing (8-k)
10/13/201507:30:00Johnson & Johnson Reports 2015 Third-Quarter Results:
10/13/201507:07:32Current Report Filing (8-k)
10/13/201506:56:03J&J to buy back $10B in shares
10/13/201506:45:00Johnson & Johnson Announces $10 Billion Share Repurchase Program
10/13/201504:40:00Global Stocks Fall on China Data
10/12/201518:05:05The Life (And Death) Of A Dividend Growth Portfolio
10/12/201509:51:19Premarket Biotech Digest: Understanding Multiple Sclerosis, Gilead's...
10/12/201509:37:42Q3 Earnings Previews: Intel, Kinder Morgan, Schlumberger, And...
10/12/201507:43:52Game Plan For The Week - Cramer's Mad Money (10/9/15)
10/12/201500:14:00Retirement Strategy: Is It Possible That I Also Reach For Yield?...
10/10/201509:59:28An Analysis Of Allergan
10/10/201506:34:00Top 5 Dividend Growth Stocks For The Zombie Apocalypse
10/10/201506:00:00Scanning The SA Family For Alpha: WmHilger1
10/09/201517:31:30Different Ways To Think About Dividend Re-Investment, Part 1
10/09/201517:05:47Current Report Filing (8-k)
10/09/201502:00:00Johnson & Johnson Announces Start of Clinical Trial of Ebola...

Johnson & Johnson and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations